{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:52:51Z","timestamp":1777107171977,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Institutional start-up funds, institutional research grant and leukemia SPORE career development grant"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41379-021-00961-0","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T11:02:38Z","timestamp":1636801358000},"page":"470-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Myelodysplastic\/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-0697","authenticated-orcid":false,"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaaren","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-4067","authenticated-orcid":false,"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8491-224X","authenticated-orcid":false,"given":"Heesun Joyce","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faezeh","family":"Darbaniyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim-Anh","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle M.","family":"Devins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-0344","authenticated-orcid":false,"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-7847","authenticated-orcid":false,"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola Dal","family":"Cin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-261X","authenticated-orcid":false,"given":"Mark J.","family":"Routbort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-021-00961-0_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/380648","article-title":"The breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats","volume":"74","author":"Barbouti","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1038\/s41379-021-00961-0_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.23755","article-title":"Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10)","volume":"89","author":"Visconte","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1038\/s41379-021-00961-0_bib3","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/leu.2016.21","article-title":"The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers","volume":"30","author":"Meggendorfer","year":"2016","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib4","doi-asserted-by":"crossref","first-page":"14251","DOI":"10.18632\/oncotarget.7350","article-title":"Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS","volume":"7","author":"Kanagal-Shamanna","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-021-00961-0_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2141.1999.01537.x","article-title":"Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder\/myelodysplastic syndrome with an aggressive clinical course","volume":"106","author":"McClure","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1038\/s41379-021-00961-0_bib6","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/cncr.26537","article-title":"Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild\u2010type TP53","volume":"118","author":"Kanagal\u2010Shamanna","year":"2012","journal-title":"Cancer"},{"key":"10.1038\/s41379-021-00961-0_bib7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00961-0_bib8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/modpathol.2015.55","article-title":"Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia","volume":"28","author":"Weinberg","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00961-0_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","article-title":"Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib10","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1038\/s41379-021-00961-0_bib11","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","article-title":"Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)","volume":"106","author":"Barosi","year":"2005","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00961-0_bib12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv."},{"key":"10.1038\/s41379-021-00961-0_bib13","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.leu.2404316","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features","volume":"20","author":"Wang","year":"2006","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.leukres.2007.07.004","article-title":"Clinical and prognostic features of patients with myelodysplastic\/myeloproliferative syndrome categorized as unclassified (MDS\/MPD-U) by WHO classification","volume":"32","author":"Cannella","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1038\/s41379-021-00961-0_bib15","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00961-0_bib16","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3324\/haematol.2012.072538","article-title":"High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic\/myeloproliferative neoplasms","volume":"98","author":"Jeromin","year":"2013","journal-title":"Haematologica"},{"key":"10.1038\/s41379-021-00961-0_bib17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","article-title":"SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts","volume":"26","author":"Visconte","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib18","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"key":"10.1038\/s41379-021-00961-0_bib19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv."},{"key":"10.1038\/s41379-021-00961-0_bib20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","article-title":"Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00961-0_bib21","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions","volume":"104","author":"Valent","year":"2019","journal-title":"Haematologica"},{"key":"10.1038\/s41379-021-00961-0_bib22","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1002\/ajh.26044","article-title":"Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia","volume":"96","author":"Montalban-Bravo","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1038\/s41379-021-00961-0_bib23","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/bloodadvances.2020002206","article-title":"Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features","volume":"4","author":"Calvo","year":"2020","journal-title":"Blood Adv."},{"key":"10.1038\/s41379-021-00961-0_bib24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib25","doi-asserted-by":"crossref","unstructured":"Shallis, R. M. & Zeidan, A. M. Myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): more than just a \u201ccatch-all\u201d term? Best Pract. Res. Clin. Haematol.33, 101132 (2020).","DOI":"10.1016\/j.beha.2019.101132"},{"key":"10.1038\/s41379-021-00961-0_bib26","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00961-0_bib27","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"key":"10.1038\/s41379-021-00961-0_bib28","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"key":"10.1038\/s41379-021-00961-0_bib29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00961-0_bib30","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)\u2014a study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bcj.2015.113","article-title":"Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1038\/s41379-021-00961-0_bib32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/bcj.2016.82","article-title":"Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1038\/s41379-021-00961-0_bib33","doi-asserted-by":"crossref","unstructured":"Piazza, R., et al. SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia (American Society of Hematology Washington, DC, 2013).","DOI":"10.1182\/blood.V122.21.2598.2598"},{"key":"10.1038\/s41379-021-00961-0_bib34","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cam4.1946","article-title":"Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia","volume":"8","author":"Faisal","year":"2019","journal-title":"Cancer Med."},{"key":"10.1038\/s41379-021-00961-0_bib36","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00961-0_bib37","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1080\/10428194.2018.1436705","article-title":"Hypomethylating agents (HMAs) effect on myelodysplastic\/myeloproliferative neoplasm unclassifiable (MDS\/MPN-U): single institution experience","volume":"59","author":"Al-Kali","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1038\/s41379-021-00961-0_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.13355","article-title":"Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations","volume":"171","author":"Adema","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1038\/s41379-021-00961-0_bib39","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"10.1038\/s41379-021-00961-0_bib40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy","volume":"28","author":"DiNardo","year":"2014","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib41","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1038\/s41375-019-0521-x","article-title":"Interaction with XPO1 is essential for SETBP1 to induce myeloid transformation","volume":"33","author":"Nguyen","year":"2019","journal-title":"Leukemia"},{"key":"10.1038\/s41379-021-00961-0_bib42","doi-asserted-by":"crossref","unstructured":"Steensma, D. P. et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia25 (2021). https:\/\/doi.org\/10.1038\/s41375-021-01328-9. Online ahead of print.","DOI":"10.1038\/s41375-021-01328-9"}],"updated-by":[{"DOI":"10.1038\/s41379-021-00985-6","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00961-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00961-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222002915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222002915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00961-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T15:00:46Z","timestamp":1680361246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222002915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0893395222002915"],"URL":"https:\/\/doi.org\/10.1038\/s41379-021-00961-0","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/s41379-021-00985-6","asserted-by":"object"}]},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelodysplastic\/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-021-00961-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1038\/s41379-021-00985-6","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}